ECSP12012184A - Polipéptidos de unión a a-beta biparatópicos - Google Patents

Polipéptidos de unión a a-beta biparatópicos

Info

Publication number
ECSP12012184A
ECSP12012184A ECSP12012184A ECSP12012184A EC SP12012184 A ECSP12012184 A EC SP12012184A EC SP12012184 A ECSP12012184 A EC SP12012184A EC SP12012184 A ECSP12012184 A EC SP12012184A
Authority
EC
Ecuador
Prior art keywords
biparatopic
beta
polypeptides
union
methods
Prior art date
Application number
Other languages
English (en)
Inventor
Martin Lenter
John Park
Cornelia Dorner-Ciossek
Pascal Merchiers
Stefan Hoerer
Lothar Kussmaul
Katharina Zimmermann
Gerald Beste
Toon Laeremans
Jo Vercammen
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of ECSP12012184A publication Critical patent/ECSP12012184A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invención se refiere a polipéptidos de unión a A-beta biparatópicos y, más específicamente, a polipéptidos de unión a A-beta biparatópicos que comprenden al menos dos dominios variables de inmunoglobulina que se unen a diferentes epítopos de A-beta. La invención también se refiere a secuencias específicas de dichos polipéptidos, métodos de su producción y métodos de uso de los mismos, incluyendo métodos de tratamiento de enfermedades tales como la enfermedad de Alzheimer.
ECSP12012184 2010-03-03 2012-09-27 Polipéptidos de unión a a-beta biparatópicos ECSP12012184A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10155339 2010-03-03

Publications (1)

Publication Number Publication Date
ECSP12012184A true ECSP12012184A (es) 2012-10-30

Family

ID=42227600

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP12012184 ECSP12012184A (es) 2010-03-03 2012-09-27 Polipéptidos de unión a a-beta biparatópicos

Country Status (24)

Country Link
US (3) US8337845B2 (es)
EP (1) EP2542579A1 (es)
JP (2) JP5826194B2 (es)
KR (1) KR20130010114A (es)
CN (1) CN102781962B (es)
AP (1) AP2012006359A0 (es)
AR (1) AR080446A1 (es)
AU (1) AU2011222980B2 (es)
BR (1) BR112012022102A2 (es)
CA (1) CA2788275A1 (es)
CL (1) CL2012002095A1 (es)
CO (1) CO6592094A2 (es)
EA (1) EA201201227A1 (es)
EC (1) ECSP12012184A (es)
MA (1) MA34025B1 (es)
MX (1) MX2012009460A (es)
NZ (1) NZ601117A (es)
PE (1) PE20130527A1 (es)
PH (1) PH12012501744A1 (es)
SG (1) SG183369A1 (es)
TN (1) TN2012000434A1 (es)
TW (1) TW201144437A (es)
UY (1) UY33253A (es)
WO (1) WO2011107507A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8337845B2 (en) 2010-03-03 2012-12-25 Boehringer Ingelheim International Gmbh A-beta binding polypeptides
US11644471B2 (en) * 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP2621953B1 (en) 2010-09-30 2017-04-05 Ablynx N.V. Biological materials related to c-met
EP3466972B1 (en) 2011-06-23 2026-03-04 Ablynx NV Serum albumin binding proteins
HUE031828T2 (en) 2011-06-23 2017-08-28 Ablynx Nv Procedures for Predicting, Detecting, and Reducing Aspiration Protein Interference in Assays Containing Immunoglobulin Variable Single Domain
US9346884B2 (en) 2011-09-30 2016-05-24 Ablynx N.V. Biological materials related to c-Met
HUE039033T2 (hu) 2012-01-10 2018-12-28 Biogen Ma Inc Terápiás molekulák transzportjának fokozása a vér-agy gáton keresztül
JP6449272B2 (ja) * 2013-07-08 2019-01-09 ナンジン レジェンド バイオテック カンパニー，リミテッドＮａｎｊｉｎｇ Ｌｅｇｅｎｄ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． タンパク質の血清半減期を増加する組成物及び方法
IL318433A (en) * 2014-05-16 2025-03-01 Ablynx Nv Improved immunoglobulin variable complexes
SG11201609162SA (en) 2014-05-16 2016-12-29 Ablynx Nv Improved immunoglobulin variable domains
US11001640B2 (en) * 2014-11-03 2021-05-11 Merck Patent Gmbh Methods for generating bispecific shark variable antibody domains and use thereof
WO2016077595A1 (en) * 2014-11-12 2016-05-19 The General Hospital Corporation Methods for treating neurodegenerative diseases
CN104558172A (zh) * 2015-01-04 2015-04-29 东南大学 一种针对β淀粉样蛋白的单域重链纳米抗体及其应用
WO2016127104A2 (en) * 2015-02-06 2016-08-11 University Of Maryland, Baltimore Tetra-specific, octameric binding agents and antibodies against clostridium difficile toxin a and toxin b for treatment of c. difficile infection
EP3603764B1 (en) * 2015-04-28 2022-03-30 Hybio Pharmaceutical Co., Ltd. High performance liquid chromatography method for polypeptide mixtures
KR102802241B1 (ko) 2015-12-04 2025-05-07 베링거 인겔하임 인터내셔날 게엠베하 종양 세포에서 wnt 신호 전달을 길항하는 바이파라토픽 폴리펩타이드
TWI887192B (zh) 2017-05-31 2025-06-21 比利時商艾伯林克斯公司 拮抗腫瘤細胞中wnt訊息傳導之多肽
CA3070253A1 (en) * 2017-07-19 2019-01-24 Vib Vzw Serum albumin binding agents
TW202000238A (zh) * 2018-02-26 2020-01-01 比利時商艾伯林克斯公司 編碼肽連接子之經改良核苷酸序列
CN112584863B (zh) 2018-08-17 2025-10-28 Ab工作室有限公司 催化抗体和其使用方法
JP2022509372A (ja) * 2018-10-29 2022-01-20 バイオジェン・エムエイ・インコーポレイテッド 血液脳関門輸送の促進のためのヒト化され安定化されたｆｃ５バリアント
CN111334480B (zh) * 2020-05-18 2020-09-01 苏州仁端生物医药科技有限公司 一种分泌抗Aβ1-42单克隆抗体的杂交瘤细胞株及其应用
WO2024133935A1 (en) 2022-12-23 2024-06-27 Ablynx Nv Protein-based conjugation carriers
WO2022020680A1 (en) 2020-07-23 2022-01-27 Othair Prothena Limited Anti-abeta antibodies
EP4221750A4 (en) * 2020-09-30 2024-11-13 Merck Sharp & Dohme LLC BINDING PROTEINS AND ANTIGEN-BINDING FRAGMENTS THEREOF BINDING TO ABETA
TW202246334A (zh) * 2021-02-02 2022-12-01 美商美國禮來大藥廠 Gitr拮抗劑及其使用方法
CN113686235B (zh) * 2021-08-16 2022-09-16 中国科学院力学研究所 一种基于纳米孔过孔电流估计蛋白质构象形貌特征的方法
AR131869A1 (es) 2023-02-17 2025-05-07 Ablynx Nv POLIPÉPTIDOS QUE SE UNEN AL RECEPTOR DE Fc NEONATAL
WO2025189977A1 (zh) * 2024-03-13 2025-09-18 寻济生物科技（北京）有限公司 一种抗vegfa融合构建体及其制备方法和应用
CN120919292A (zh) * 2025-08-04 2025-11-11 首都医科大学宣武医院 用于预防或治疗阿尔茨海默病的Aβ-Tau多表位疫苗及其用途

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1621554E (pt) 1992-08-21 2009-07-13 Univ Bruxelles Imunoglobtainas desprovidas de cadeias leves
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
EP1274720A4 (en) 2000-04-12 2004-08-18 Human Genome Sciences Inc FUSION PROTEINS CONTAINING ALBUMIN
US7943129B2 (en) 2000-05-26 2011-05-17 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
AU2002319402B2 (en) 2001-06-28 2008-09-11 Domantis Limited Dual-specific ligand and its use
JP4123856B2 (ja) 2001-07-31 2008-07-23 日油株式会社 生体関連物質の修飾剤およびポリオキシアルキレン誘導体の製造方法
EP1463752A4 (en) 2001-12-21 2005-07-13 Human Genome Sciences Inc ALBUM INFUSION PROTEINS
AR038568A1 (es) 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
FR2846667B1 (fr) 2002-11-06 2004-12-31 Pasteur Institut Fragments variables d'anticorps de camelides a chaine unique diriges contre le peptide beta-amyloide 1-42 et leurs applications pour le diagnostic et le traitement des maladies neuroagregatives
EP1558647B1 (en) 2002-11-08 2015-06-10 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
EP2284192A3 (en) * 2002-11-08 2011-07-20 Ablynx N.V. Camelidae antibodies for sublingual administration
JP4490290B2 (ja) 2002-12-31 2010-06-23 ネクター セラピューティクス アラバマ，コーポレイション 加水分解安定性マレイミド末端ポリマー
PE20050627A1 (es) 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
SI1639011T1 (sl) 2003-06-30 2009-04-30 Domantis Ltd Pegilirana protitelesa z enojno domeno (dAb)
PT1687338E (pt) 2003-11-07 2011-01-20 Ablynx Nv Anticorpos de domínio único vhh de camelídeos direccionados para o receptor do factor de crescimento epidérmico e suas utilizações
EP1699810A4 (en) 2003-12-17 2009-10-21 Elan Pharm Inc A BETA IMMUNOGENIC PEPTIDE CARRIER CONJUGATE AND METHOD FOR THE PRODUCTION THEREOF
WO2006040153A2 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
CN101076543A (zh) * 2004-10-13 2007-11-21 阿布林克斯公司 用于治疗和诊断变性神经疾病如阿尔茨海默症的单结构域骆驼抗淀粉样蛋白β的抗体以及包含它的多肽
ES2396555T3 (es) 2004-12-15 2013-02-22 Janssen Alzheimer Immunotherapy Anticuerpos que reconocen péptido beta amiloide
US20060257396A1 (en) 2004-12-15 2006-11-16 Jacobsen Jack S Abeta antibodies for use in improving cognition
PE20061329A1 (es) 2004-12-15 2006-12-08 Neuralab Ltd Anticuerpos ab humanizados para mejorar la cognicion
CA2589860A1 (en) 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
PE20061323A1 (es) 2005-04-29 2007-02-09 Rinat Neuroscience Corp Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
AU2006249144B2 (en) 2005-05-18 2011-11-17 Ablynx Nv Improved NanobodiesTM against Tumor Necrosis Factor-alpha
MX2007014564A (es) * 2005-05-20 2008-02-07 Ablynx Nv Anticuerpos de vhh de dominio unico contra el factor de von willebrand.
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
JP5364870B2 (ja) * 2005-08-19 2013-12-11 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
US20100323905A1 (en) 2005-09-23 2010-12-23 Academisch Ziekenhuis Leiden Vhh for the Diagnosis, Prevention and Treatment of Diseases Associated with Protein Aggregates
MX2008007477A (es) 2005-12-12 2008-09-03 Ac Immune Sa Anticuerpos monoclonales especificos 1-42 beta con propiedades terapeuticas.
CA2632828C (en) 2005-12-12 2012-07-10 F. Hoffmann-La Roche Ag Antibodies against amyloid beta with glycosylation in the variable region
DK2177536T3 (da) 2006-03-30 2014-07-14 Glaxo Group Ltd Antistoffer mod amyloid-beta-peptid
NZ574188A (en) 2006-07-14 2012-05-25 Ac Immune Sa Humanized antibody against amyloid beta
CA2666599A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
WO2008068280A1 (en) 2006-12-05 2008-06-12 Ablynx N.V. Peptides capable of binding to serum proteins
CN101553504A (zh) 2006-12-11 2009-10-07 豪夫迈·罗氏有限公司 Aβ抗体胃肠外制剂
AU2007331672A1 (en) * 2006-12-15 2008-06-19 Ablynx N.V. Amino acid sequences that modulate the interaction between cells of the immune system
CA2675847C (en) 2007-01-18 2014-12-30 Eli Lilly And Company Pegylated a.beta. fab
EP1978035A1 (en) 2007-04-05 2008-10-08 Hans-Knöll-Institut Leibniz-Institut für Naturstoff-Forschung Anti-amyloid antibodies and their use in diagnosis and therapy of amyloid diseases
KR101264473B1 (ko) 2007-05-24 2013-05-29 아블린쓰 엔.브이. Ｒａｎｋ-ｌ에 대한 아미노산 서열, 및 이를 포함하는 골 질환 및 장애 치료용 폴리펩티드
PE20090329A1 (es) 2007-05-30 2009-03-27 Abbott Lab Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos
EP2527366B1 (en) 2007-06-12 2017-08-16 AC Immune S.A. Monoclonal anti beta amyloid antibody
DK2170389T3 (en) 2007-06-12 2015-01-19 Ac Immune Sa Humanized antibodies against amyloid beta
EP2009445A1 (en) 2007-06-29 2008-12-31 Institut Pasteur Use of a camelid single-domain antibody for detecting an oligomeric form of an amyloid beta peptide and its applications
EP2008666A1 (en) * 2007-06-29 2008-12-31 Institut Pasteur Use of VHH antibodies for the preparation of peptide vectors for delivering a substance of interest and their applications
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
CA2703825A1 (en) 2007-10-29 2009-05-07 Innogenetics Nv New antibodies specific of the .beta.-amyloid peptides and their uses as diagnostic agents or drugs
WO2009068631A1 (en) * 2007-11-27 2009-06-04 Ablynx N.V. Method for obtaining polypeptide constructs comprising two or more single domain antibodies
CA2717015A1 (en) 2008-03-05 2009-09-11 Ablynx Nv Novel antigen binding dimer-complexes, methods of making and uses thereof
CN102089325A (zh) 2008-04-17 2011-06-08 埃博灵克斯股份有限公司 能够结合血清白蛋白的肽，以及包含其的化合物、构建体和多肽
PE20100054A1 (es) * 2008-06-03 2010-03-03 Abbott Lab Inmunoglobulina con dominio variable dual
US8337845B2 (en) 2010-03-03 2012-12-25 Boehringer Ingelheim International Gmbh A-beta binding polypeptides

Also Published As

Publication number Publication date
CN102781962A (zh) 2012-11-14
AU2011222980B2 (en) 2016-08-11
SG183369A1 (en) 2012-09-27
MX2012009460A (es) 2012-09-12
JP2013520974A (ja) 2013-06-10
UY33253A (es) 2011-09-30
US8337845B2 (en) 2012-12-25
AU2011222980A1 (en) 2012-08-02
US20140030275A1 (en) 2014-01-30
AP2012006359A0 (en) 2012-08-31
HK1175184A1 (en) 2013-06-28
AR080446A1 (es) 2012-04-11
CL2012002095A1 (es) 2012-10-19
US8614308B2 (en) 2013-12-24
US9211330B2 (en) 2015-12-15
BR112012022102A2 (pt) 2017-01-10
CN102781962B (zh) 2014-12-10
TW201144437A (en) 2011-12-16
PH12012501744A1 (en) 2021-08-09
EP2542579A1 (en) 2013-01-09
MA34025B1 (fr) 2013-02-01
TN2012000434A1 (en) 2014-01-30
KR20130010114A (ko) 2013-01-25
JP2015180691A (ja) 2015-10-15
EA201201227A1 (ru) 2013-04-30
PE20130527A1 (es) 2013-05-09
CA2788275A1 (en) 2011-09-09
CO6592094A2 (es) 2013-01-02
NZ601117A (en) 2014-06-27
US20130017209A1 (en) 2013-01-17
WO2011107507A1 (en) 2011-09-09
US20120058118A1 (en) 2012-03-08
JP5826194B2 (ja) 2015-12-02

Similar Documents

Publication Publication Date Title
CO6592094A2 (es) Polipeptidos de union a a-beta biparatopicos
UA115402C2 (uk) Cd3-зв'язувальна молекула, здатна до зв'язування з cd3 людини і cd3, що не є людським
CY1122278T1 (el) Αντι il-36r αντισωματα
AU2018256498A1 (en) Antibodies to amyloid beta
CY1119567T1 (el) Θεραπευτικα πεπτιδια
EA201590998A1 (ru) СВЯЗЫВАЮЩИЕСЯ С EGFR И c-Met МОЛЕКУЛЫ С ДОМЕНАМИ ФИБРОНЕКТИНА ТИПА III
WO2014004549A3 (en) Anti-mesothelin binding proteins
HK1211599A1 (en) Il-6 antagonists and uses thereof
EA201690447A1 (ru) БИСПЕЦИФИЧЕСКИЕ МОНОВАЛЕНТНЫЕ ДИАТЕЛА, КОТОРЫЕ СПОСОБНЫ СВЯЗЫВАТЬСЯ С gpA33 И CD3, И ИХ ПРИМЕНЕНИЯ
EA201490677A1 (ru) Связывающие антиген cd27l белки
ECSP13013001A (es) Moléculas de unión biespecíficas que se unen a vegf y ang2.
WO2017136562A3 (en) Bispecific binding proteins for pd-l1 and kdr
EA201791485A1 (ru) Анти-cd47-антитела и их применения
BR112014028785A2 (pt) proteínas de ligação a antígeno de st2
EA201890315A1 (ru) Молекулы антител, связывающие cd22
BR112014019611A2 (pt) agentes de ligação mica
EA201291039A1 (ru) Антитела, связывающие cd27 человека, и их применение
UA110049C2 (uk) ЛІКУВАННЯ ОСТЕОАРТРИТУ ІМУНОГЛОБУЛІНОВИМ ЗВ'ЯЗУВАЛЬНИМ БІЛКОМ З ПОДВІЙНИМ ВАРІАБЕЛЬНИМ ДОМЕНОМ, ЩО ЗВ'ЯЗУЄ IL-1α І IL-1β
SG10201902924RA (en) Antibodies that bind ebola glycoprotein and uses thereof
HK1206638A1 (zh) 用於生产化妆品蛋白质和肽的修饰的多核苷酸
EA201291067A1 (ru) Гуманизированные антигенсвязывающие белки к миостатину
MX2015011772A (es) Anticuerpos anti-hepcidina y usos de los mismos.
EA201490717A1 (ru) АНТИТЕЛА К ErbB3 И ИХ ПРИМЕНЕНИЕ
EA201401204A1 (ru) Антитела к il-23p19
EA201591993A1 (ru) Лечение склеродермии с применением комбинированной терапии антителами анти-ccl2 и анти-loxl2